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ABSTRACT
Prevention of preterm birth and subsequent newborn immaturity is a primary goal of obstetrical
care worldwide. Accumulated evidence shows that 1) as many as 25-50% of preterm births are
caused by common genital tract infections and subsequent maternal/fetal inflammatory responses;
2) microbial and maternal host factors (phospholipases, proteases, etc.) play roles in preterm labor
and preterm premature rupture of membranes (pPROM); 3) integrated aspects of maternal and
fetal host responses (inflammation, altered immune adaptations, endocrine and paracrine mecha-
nisms) play increasingly understood roles in premature activation of parturition; and 4) identifica-
tion and systemic treatment of common genitourinary infections, most importantly bacterial vagi-
nosis (BV), reduce the risks of preterm delivery and PROM. Infect. Dis. Obstet. Gynecol. 5:106-
114, 1997. (C) 1997 Wiley-Liss, Inc.
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".Infection in thefemale reproductive tract (especially in
the cewix) can cause premature rupture of membranes
and induce premature labor.... This process is respon-
siblefor many preventable infant deaths.
1,,
estational age at birth and birth weight are the
most important biologic determinants world-
wide of an individual child’s chances of survival
and healthy growth, e Immediate sequelae of bio-
logic immaturity at birth include respiratory dis-
tress, intraventricular hemorrhage, leukomalacia,
necrotizing enterocolitis, prolonged hospitalization,
and death.3,4 Among survivors, life-long complica-
tions can include cerebral palsy, cognitive impair-
ment, blindness, and deafness.3,4 The direct and
indirect costs of biologic immaturity at birth can be
immense. Estimates of the excess direct medical
costs attributable to preterm infants totaled $6 bil-
lion U.S. in 1988.s The total individual, family, and
societal burdens imposed by biologic immaturity at
birth are beyond measure.
BACTERIAL VAGINOSIS (BV) AND
PRETERM BIRTH
The evidence for microbial causes of preterm birth
is most extensive and convincing for BV. Never-
theless, there is continuing misapprehension that
lower reproductive tract infections and BV are
"mere markers" of upper tract intrauterine infec-
tion.6 BV is not truly an infection, but rather a mi-
croecological condition in which there are dramatic
alterations in the endogenous vaginal microflora.
Hydrogen peroxide-producing Lactobadllus strains
(including L.jensenii and L. crispatus) are reduced in
number. :,s BV features multilog population in-
creases in a characteristic set of microflora which
includes Gardnerella vaginalis, genital anaerobes,
and genital mycoplasmas.: These microbes, along
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with coliforms and streptococci, are the same as
found in most cases of chorioamnionitis.9’1 BV is
associated with increased vaginal and cervical fluid
concentrations of endotoxin, proteases, mucinases,
sialidases, IgA proteases, and phospholipases Az
and C. 11-16 Observational studies show that the
presence of BV early in pregnancy is associated
with second trimester labor and perinatal loss or
so-called late miscarriage.6,17
Multiple studies have been completed world-
wide which demonstrate consistent associations
of preterm birth with BV as well as our ability to
reduce the risks with systemic (oral) treat-
merit.6,,1,16-9 Table displays findings of stud-
ies linking BV and preterm birth and/or premature
rupture of membranes (PROM). Table 2 shows the
results of intervention studies targeted at BV to
reduce risks of prematurity as well as neonatal and
maternal sequelae.
This and other information indicates that 1) BV
is a direct cause of adverse pregnancy outcomes
rather than a surrogate marker and 2) ascending
infection or abnormal lower reproductive tract mi-
croflora mediate adverse pregnancy outcomes.
Similar microbe-host interactions occur in peri-
odontal disease and peptic ulcer disease, which are
also effectively treated with antimicrobial agents,
including metronidazole and clindamycin. How de-
mographic, behavioral, obstetric, and infection fac-
tors interact with BV or other microbe-associated
conditions is under continuing investigation. Fig-
ure 1 describes an "illness script" which depicts
how some of these interactions may occur.
MICROBIAL PATHOGENESIS
Microorganisms can act directly on reproductive
tract tissues to initiate preterm labor and PROM or
perpetuate these processes possibly begun by other
factors. Microorganisms produce a variety of pro-
teolytic enzymes including matrix metalloprote-
ases, i.e., collagenases, elastases, IgA proteases,
mucinases, and sialidases. 3-16,2-23 These pluripo-
tential enzymes are involved in aspects of microbe
pathogenesis including attachment, overcoming
maternal host defenses, as well as directly impair-
ing fetal membrane strength and elastic-
ity.1-6,2-z3 Presence of enzymes such as siali-
dases, which facilitate bacterial attachment and
break down mucin, may be required to facilitate
attachment while mucinases may assist microbe as-
cent into uterine tissues, a6 Proteolytic enzymes
may act directly on cervical collagen and amnion-
chorion leading to premature cervical ripening and
weakening of the fetal membranes with subse-
quent preterm PROM (pPROM).z-zz Collagen
biosynthesis may be disrupted by phospholipase
Az- or C-mediated prostaglandin release as well as
specific microbial or host proteolytic enzymes,
a3
Similarly, proteases may act as immunogenic
agents and activate or amplify host inflammatory
responses,z3
Vaginal fluid levels of endotoxin, sialidases,
phospholipase Az (PLAz), prostaglandin E z
(PGEz), and interleukin-1 are greatly increased
among women with BV.1-6 Increased levels of
vaginal PLAz are directly associated with increased
risks of preterm labor and birth.1 Trichomoeas vagi-
ealis also directly produces PLAz, as well as a num-
ber of proteolytic enzymes in vitro,z,z4
HOST INFLAMMATORY PROCESSES
Dynamic maternal and fetal host inflammatory pro-
cesses are of paramount importance in the patho-
genesis of infection-mediated preterm birth and
PROM. Multiple lines of cellular, animal model,
and clinical investigation confirm evidence of in-
flammation in both maternal and fetal tissues in the
pathogenesis of some but not all instances of pre-
maturity. These findings include the presence of
inflammatory mediators such as interleukin-l-[3,
interleukin-6, interleukin-8, and tumor necrosis
factor-et (TNF-c) more often within the amniotic
fluid of women with 1) amniotic fluid infection, 2)
PROM, and 3) among women who continue pre-
term labor to delivery compared with women in
whom preterm labor is successfully inter-
rupted.9,zs- Recent investigations show that in-
creased levels of interleukin-6 are detectable
within cervical fluid ofwomen with idiopathic pre-
term labor who have intraamniotic fluid infection
and among women during antenatal care who sub-
sequently deliver prior to 37 weeks gestation.
In vitro and animal model studies confirm and
inform clinical studies showing causal relationship
between infection and preterm birth. Interleukin-
1, interleukin-6, and TNF-c production have been
demonstrated by cultured human decidual cells
stimulated by bacterial products.,zs,3 Similarly,
amnion or decidual explants have been shown to
produce prostaglandins in response to these cyto-
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 107TABLE I. Review of the literature evaluating specific microorganisms and PTB, LBW, or pPROM
Gesta-
tional
age
tested
Microorganism Study design (weeks) Positive Negative Outcome
Risk ratio
(95% CI)
BV
Minkoff, 1984
Gravett, 1986
Prospective cohort 13 ND ND PTB
Prospective cohort 32 24/102 (24.0%) 65/432 (15.0%) LBW
22/102 (21.6%) 44/432 (10.2%) pPROM
Prospective cohort 22-28 3 I/I 35 (23%) 97/651 (I 5%) PTB
ND ND pPROM
Prospective cohort 8-17 11/162 (6.8%) 6/571 (I.0%) PTB
6/162 (3.7%) 3/571 (0.5%) pPROM
Prospective cohort 16-20 17/84 (20.2%) 48/406 (I 1.8%) PTB
28-32 11/67 (16.4%) 50/395 (12.7%) PTB
16-26 14/I 29 (I 0.9%) 4/I 22 (3.3%) PTB
McDonald et al.,
1991
0
Kurki et al.,
1992
8
Joesoef, 1993
McGregor et al., Prospective cohort
1994
6
Hay et al., 19946 Prospective cohort
McGregor et al., Prospective cohort
19957
Meis et al., 199548 Prospective cohort
Hillier et al., Prospective cohort
199519
Trichomonas vaginalis
Grice, 19744s Retrospective chart
review
Ross, 1983 Prospective cohort
Hardy, 1984 Prospective cohort
Joesoef, 1993 Prospective cohort
Read, 1993 Prospective cohort
McGregor et al., Prospective cohort
1995
6
Cotch, 199044 Prospective cohort
Meis et al., Prospective cohort
199548
Chlamydia trachomatis
Harrison, 1983 Prospective cohort
Gravett, 1986 Prospective cohort
Sweet, 1987 Prospective cohort
McGregor et al., Prospective cohort
199038
Ryan et al., 19904 Prospective cohort
Cohen et al., Prospective cohort
199042
Martin et al., Prospective cohort
199043
Donder, 1993 Prospective cohort
Neisseria gonorrhoeae
Amtsey, 1976 Retrospective chart
review
Edwards, 1978 Prospective matched
pair
Donders, 1993 Prospective cohort
Elliott, 1990 Case control
6/128 (4.7%) 1/121 (0. I%)
<16 7/57 (I 2.3%) 9/384 (2.3%)
<24 8/83 (9.6%) 18/616 (2.9%)
18 31/165 (I 8.8%) 37/380 (9.7%)
10/144 (6.9%) 7/350 (2.0%)
24 ND ND
28 ND ND
23-26 77/I,218 (6.3%) 291/6,978 (4.2%)
35/I, 132 (3. I%) 182/6,617 (2.8%)
ND 17/748 (2.3%) 76/7,482 (I .0%)
<34 ND (I 2.0%) ND (7.0%)
13 ND (I 8.0%) ND (6.7%)
16-20 ND ND
23-26 ND (I 5.4%) ND (9.9%)
18 8/50 (I 6.0%) 56/460 (I 2.2%)
3/45 (6.7%) 14/418 (3.4%)
23-26 ND (I 4.8%) ND (I 1.0%)
ND (4.0%) ND (2.8%)
24 ND ND
28 ND ND
<32 7/17 (41.2%) 74/790 (9.4%)
13--42 ND (32.0%) ND (I 5.0%)
ND (23.0%) ND (11.0%)
221304 (7.2%) 43316,242 (6.9%)
30 (3.%) 0/, (.%)
ND ND
st visit
22-29
st visit
22-30
23-26
st visit
218/I,I 10 (I 9.6%) 1,068/9,1 (I 1.7%)
58/I, 110 (5.2%) 243/9, (2.7%)
16/79 (20.2%) 18/244 (7.3%)
2.3 (0.96-5.5)
1.7 (I .0-2.9)
2.0 (I. I-3.7)
1.8 (I .01-3.2)
2.7 (I. I-6.5)
6.9 (2.5-18.8)
7.3 (I .8-29.4)
2.0 (I .0-3.9)
1.5 (0.7-3.0)
3.3(I.2-9.1)
pPROM 5.7 (0.9-36. I)
PTB 5.2 (2.0-I 3.5)
PTB 3.3 (I .5-7.4)
PTB 1.9 (I .2-3.0)
pPROM 3.5 (I .4-8.9)
PTB <35 weeks 1.4 (0.9-2.0)
PTB <35 weeks 1.8 (I.2-3.0)
PTB + LBW 1.4 (I. I-I.8)
pPROM I. (0.8-1.6)
pPROM 2.2 (I .3-3.7)
LBW 1.7 (0.8-3.7)
LBW 2.6 (I. I-5.9)
PTB 1.8 ND
PTB 1.4 (I.2-1.8)
PTB 1.6 (0.8-3.2)
pPROM 2.0 (0.6-6.7)
PTB 1.3 (I. I-I.4)
pPROM 1.2 (0.9-1.5)
PTB <35 weeks 1.5 (0. I-I.8)
PTB <35 weeks 0.9 (0.2-3.6)
pPROM 4.4 (2.4-8. I)
LBW 2.7 (I .3-5.7)
pPROM 2.4 (I. I-5.4)
PTB 1.05 (0.6-1.7)
pPROM 2.0 (I .2-3.7)
PROM 2.5 (I. I-5.7)
LBW 1.7 (1.5-1.9)
pPROM 2. (1.6-2.9)
PROM 2.8 (I .5-5. I)
28/520 (5.4%) 67/2,250 (3.0%) pPROM 1.8 (I .2-2.8)
6/22 (27%) 23/145 (I 6%) PTB 2.0 (0.6-6. I)
ND 561198 (28.3%) 55714,246 (I 3. I%) PTB 2.6 (I .9-3.6)
ND 8119 (42. I%) 5141 (I 2.2%) PTB 5.2 (I .2-23.8)
st visit SI9 (S6.0%) 2411 S8 S.0%) PTB 6.0 .S-34.0)
At delivery ND (I 1.2%) ND (3.8%) PTB 5.3 (I .6-17.9)
apROM preterm premature rupture of membranes; PTB preterm birth <37 weeks gestation; LBW low birth weight; ND not described.
brisk ratio and 95% confidence intervals calculated from data provided.
CGroup with frequent intercourse and T. vaginalis vs. no T. vaginalis.PREVENTING PRETERM BIRTH MEDIATED BYINFECTION McGREGOR AND FRENCH
TABLE 2. Literature review which examined treatment for specific infections and PTB
Study
Microorganism design Subjects Outcome
Risk ratio
Treated Control (95% CI)
N. gonorrhoeae
Charles, 1970 Open retrospective ND PROM
comparison
C. trachomatis
Martin et al., RCT, double blind
199043 placebo
Ryan et al., Clinical trial, control
19904 observational
control
Cohen et al., Open retrospective
199042 comparison
BV
Hillier et al., Observation
1995
9
Meis et al., Observation
199548
McGregor et Clinical trial,
al., 19957 observational
control
Morales et al., RCT, double blind
199449 placebo
McDonald et RCT, double blind
al., 1996s placebo
Hauth et al., RCT, double blind
199547 placebo
T. vaginalis
Morgan, 1978 Observation
Ross, 1983 Observation
McGregor et Clinical trial,
al., 199517 observational
control
All LBW
PTB
pPROM
All LBW
pPROM
All PTB
All PTB + LBW
All
All
Prior PTB
All
Prior PTB
Prior PTB or
<50 kg
All
All
All
Treated Untreated
4/144 (2.8%) 6/14 (43%) 0.06 (0.02-0.2)
Erythromycin Placebo
7/89 (7.9%) 18/85 (21.2%) 0.37 (0.16-0.84)
9/89 (10.1%) 17/85 (20%) 0.51 (0.24-1.07)
1/87 (I.1%) 6/81 (7.4%) 0.16 (0.02-1.26)
Treated Untreated
145/I,323 (I 1.0%) 218/I,I 10 (19.6%) 0.56 (0.46-0.68)
39/I,323 (2.9%) 58/I, I0 (5.2%) 0.56 (0.38-0.84)
Erythromycin Untreated
7/244 (2.9%) 1/79 (I 3.9%) 0.16 (0.06-0.47)
Treated Untreated
8/187 (4.3%) 77/I,218 (6.3%) 0.68 (0.33-1.38)
Treated
PTB <35 weeks ND
Untreated
ND 0.44 (0. I-I .9)
Clindamycin No treatment
PTB 18/183 (9.8%) 31/165 (I 8.8%) 0.5 (0.3-0.9)
pPROM 6/171 (3.5%) 10/144 (6.9%) 0.5 (0.2-1.4)
Metronidazole Placebo
PTB 8/44 (I 8.0%) 16/36 (39.0%) 0.41 (0.2-0.8)
pPROM 2/44 (4.5%) 12/36 (33.3%) 0.14 (0.03-0.57)
Metronidazole Placebo
PTB ND (5.1%) ND (6.4%) 0.8 (0.3-1.8)
PTB 2/20 (I 0%) 10/24 (42%) 0.16 (0.02-0.9)
Metronidazole + Placebo
erythromycin
PTB 54/172 (31%) 42/86 (49%) 0.6 (0.5-0.9)
Metronidazole No treatment
LBW 10/597 (17.5%) 53/283 (18.5%) 0.95 (0.7-1.28)
PTB 32/597 (5.3%) 13/283 (4.5%) I. 17 (0.6-2.19)
Treated No treatment
LBW ND (I 2.0%) ND (I 1.0%) ND
Metronidazole No treatment
PTB 7/48 (I 4.6%) 8/50 (I 6.0%) 0.9 (0.34-2.3)
pPROM 2/43 (4.6%) 3/45 (6.7%) 0.5 (0.2-1.4)
aSee Table for abbreviations. RCT =.
brisk ratio and 95% confidence intervals calculated from data provided.
kines and endotoxin.9,33 The work of Gravett et
al.34,s with a monkey model of amniotic fluid in-
fection demonstrates sequential increases in amni-
otic fluid concentrations of TNF-c, interleukin-6,
interleukin-1-13, interleukin-1 receptor antagonists,
PGEz and Fz following intraamniotic inoculation
of group B streptococcus. Furthermore, onset of
uterine contractions ultimately leading to preterm
labor and delivery occurred sequentially approxi-
mately 10 h following detection of rising amniotic
fluid levels of interleukin-1 and parallel rises of
prostaglandins PGE 2 and F2o.
34,35 Subsequent
work with this model demonstrates TNF-ot, PGEz
and F2 following infusion of interleukin-l-13 in the
absence of microorganisms.
36 Levels of TNF-ot
and interleukin-l-13 were cleared within 48 h; how-
ever, prostaglandin levels remained elevated.36
These and other cytokines directly contribute to
increased levels of uterotonic prostaglandins.36
Such cytokines may also contribute to the onset of
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Enabling conditions
Predisposing factors
Boundary conditions
Proximate cause/fault
Consequences
Interventions
Results of interventions
I. Absence protective Lactobacilli
2. Sexual exposure to partner
with "BV set" of microbes
3. Genetic predisposition
I. First or second trimester
bleeding
2. Short or funneled cervix
3. Increased uterine activity
4. Increased vaginal fluid PLA2,
proteases
5. Concomitant reproductive tract
infections
I. Black race, age
I. Invasion intrauterine tissues by
microorganisms
2. Inflammatory response,
maternal-fetal tissues
I. Preterm labor
2. Preterm premature rupture of
membranes
I. Systemic antibiotic .treatment:
metronidazole, clindamycin,
others
2. Reduce uterine contractions
I. Reduced preterm birth, pPROM
2. Reduced direct, indirect costs
3. Reduced long-term morbidity
Fig. I. "Illness script" for BV-mediated preterm birth/PROM.
preterm birth by induction of matrix metalloprote-
ases, which in turn enhance cervical ripening and
weakening of the amnionchorion.37
Experiments performed with human fetal mem-
branes show that substances produced by both mi-
crobes and host inflammatory cells have been
shown to mediate prostaglandin release and mem-
brane weakening in vitro.21,22 Importantly, addi-
tion of appropriate antimicrobials including eryth-
romycin and metronidazole during in vitro experi-
ments of fetal membrane tensile strength prevents
bacteria-induced fetal membrane weakening.28,38
Choice of antibiotics to treat infectious agents in
both in vitro and in vivo and clinical investigations
regarding preterm birth is crucial: agents such as
clindamycin, erythromycin, aminoglycosides, and
metronidazole tend to shut down bacterial viru-
lence factor production. Conversely, beta lactam
antibiotics (penicillins, cephalosporins) act primar-
ily by impairing cell wall synthesis, allowing for
increased local tissue release of bacterial cell con-
stituents, including endotoxins [lipopolysacchari-
des (LPS)]. Use of bactericidal antibiotic agents
may "throw gasoline" on the "fire of inflamma-
tion" and thus worsen outcomes. Further under-
standing of the nature and timing of microbe-
maternal and fetal interactions and how best to
interfere with these processes will lead to develop-
ment of improved regimens for both prevention
and treatment of preterm birth mediated by repro-
ductive tract infection and inflammation.
OBSTETRICAL STUDIES: CHLAMYDIA,
GONORRHEA, AND TRICHOMONIASIS
Past observation and anecdotal studies (Table 1)
show that treatment for Neisseria gonorrhoeae and
Chlamydia trachomatis provides benefits in terms of
reduced rates of preterm birth and PROM as well
as prevention of ophthalmia neonatorum (Table
2).39-42 Retrospective comparisons of women who
received antenatal treatment for N. gonorrhoeae
compared with untreated women demonstrated
significant reductions of preterm birth and rupture
of membranes.39 Ryan and colleagues41 reported
significant reductions in the rate of low birth
weight infants [odds ratio (OR) 0.56, 95% confi-
dence interval (CI) 0.46-0.68] born to women who
received antenatal treatment for C. trachomatis
compared with retrospective, untreated control
women. Similarly, Cohen and colleagues4e de-
scribed an 84% (OR 0.16, 95% CI 0.06-0.47) re-
duction in the rate of preterm birth among success-
fully treated, chlamydia-positive women compared
with a retrospective control group of untreated
chlamydia-positive women. Among results pre-
sented from the Vaginal Infections and Prematurity
(VIP) study, Martin et al.43 reported that among
women enrolled at the New Orleans site, low birth
weight (erythromycin treated 7.9% vs. placebo
treated 21.2%, P 0.01) and PROM (erythromycin
treated 1.2% vs. placebo treated 7.4%, P 0.04)
were each significantly reduced among chlamydia-
positive women who received erythromycin com-
pared to women who received placebo. The VIP
study also showed a 40% increased risk of low birth
weight and prematurity if subjects suffered tricho-
moniasis.44 Results of this large study confirm the
role of Trichomonas vaginalis in preterm birth shown
in prior smaller investigations.4s,46
INTERVENTION STUDIES VS. BV TO
REDUCE RISKS OF PRETERM LABOR AND
RUPTURE OF MEMBRANES
Recently published controlled trials demonstrate
that important proportions of preterm births can be
prevented in women considered to be at both
110 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYPREVENTING PRETERM BIRTH MEDIATED BYINFECTION McGREGOR AND FRENCH
"high" or "normal" risk for preterm birth by
screening for and treating asymptomatic BV in
pregnancy (Table 2). Large studies by Hillier et
al. 19 and Hauth et al.47 add conclusive weight to
well over a dozen prior studies linking BV and pre-
maturity. Hillier et al. 19 reported the most recently
analyzed portion of the large, multicenter VIP
study of over 10,000 U.S. women. There was a 40%
increase in low birth weight in women with asymp-
tomatic, untreated BV. 19 Treatment with agents ef-
fective against BV (metronidazole) eliminated this
excess risk. 19 Meis et al.48 noted a similar finding in
an observational study in North Carolina.
Hauth and colleagues47 performed a placebo-
controlled intervention trial using a 7 day course of
oral metronidazole (500 mg twice daily) and en-
teric-coated erythromycin (300 mg twice daily) in
women judged to be at increased risk of preterm
birth owing to a prior history of short gestation or
maternal low body mass (<50 kg). This combined
regimen reduced risks of preterm birth in subjects
with asymptomatic BV by approximately one-third
in both risk groups.47 In a subsequent analysis,
treated women with no other identified causes of
preterm birth had risks of PROM reduced by ap-
proximately 70% (Hauth, personal communica-
tion).
Such dramatic findings confirm those of a 1994
investigation by Morales et al.49 in which women
with both a history of prior preterm birth and find-
ings of BV in the studied pregnancy were treated
with either oral metronidazole or placebo. Morales
et al.49 similarly obtained approximately 70% re-
ductions for prematurity, low birth weight, hospital
admissions for preterm labor, and PROM.
Most recently, results from a randomized pla-
cebo-controlled treatment trial of two g oral doses
of metronidazole vs. placebo among Australian
women with heavy growth (3-4+) of Gardnerella
vaginalis isolated from the vagina (as a surrogate for
BV) demonstrated a two-thirds reduction in the
rate of preterm birth among women who had had a
prior preterm birth and 35% reduction among
women without this history,s In each of these
cited studies, the beneficial effects were demon-
strated in asymptomatic women; symptomatic sub-
jects were treated outside of these protocols and
eliminated from analysis.47’49’s
We conducted a large controlled, prospective
evaluation of "screening and treating" prevalent
infections in order to reduce preterm birth in Den-
ver, CO. 17 We demonstrated that "routine" screen-
ing and systemic treatment of prevalent reproduc-
tive tract infections, including BV, in pregnancy
reduces the occurrence of preterm birth and
PROM by approximately 50% (1,260 patients, in-
tent to treat analysis). 17 Treatment of BV with 300
mg oral clindamycin twice daily for 7 days reduced
idiopathic preterm birth by 70%; there was a single
instance of severe diarrhea. 17 Combination of BV
and other prevalent infections such as trichomoni-
asis and/or common obstetric complications such as
first trimester bleeding increased preterm birth to
more than 30%; treatment with Centers for Disease
Control (CDC)-recommended systemic (oral or in-
tramuscular) treatments reduced risks of preterm
birth by half in these multiply infected women
(Table 3).
COST BENEFIT/SAVINGS ANALYSIS
Recent economic models of preterm birth preven-
tion focus on "added costs" of diagnosis and treat-
ment of BV during pregnancy rather than economic
savings obtained from preventing preterm birth,s
Using conservative assumptions (585,000 cases of
BV in U.S. pregnant women in 1993; costs of ge-
neric antibiotic treatment associated to be $29
U.S.), Oleen-Burkey and Hilliers estimated direct
savings by preventing preterm birth caused by BV
of $150 million annually. In this study, costs for
diagnosis were assumed to be $20 U.S. for evalu-
ating Amsel’s clinical criteria or a gram stain of
vaginal fluid,sa Bloom and Leesz calculated a 25:1
direct cost savings for identifying and treating BV
among "high risk" women. Neither of these mod-
els takes into account costs incurred after neonatal
discharge or increased liability costs owing to
avoidable adverse pregnancy outcomes,s
Other genitourinary tract infections such as chla-
mydia endocervicitis, trichomoniasis, and gonor-
rhea as well as asymptomatic bacteriuria are already
sought out and treated as "standard of care" in
most U.S. centers. Partners of pregnant women
with sexually transmitted diseases should be
treated and tests of cure should be performed as
appropriate. Tests of cure for infected pregnant
women and their partners with sexually transmit-
ted disease are more urgent during pregnancy so as
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to 1) maximally reduce risks of preterm birth and 2)
eliminate risks of neonatal ophthalmia and pneu-
monitis caused by "family pathogens." These costs
are already provided for in contemporary obstetric
care.
CONCLUSIONS
Preterm birth continues as an urgent international
health priority as well as a widely accepted measure
of effective health delivery. Children born with the
biologic disadvantages of prematurity necessitate
intensive care and expenditures of immense hu-
man and economic resources. Surviving children
frequently lead lives of diminished personal and
economic potential. Clearly, the morbidity and ex-
cess costs caused by preterm birth are better pre-
vented or mitigated prior to birth than dealt with in
intensive care settings, specialized schools, and
sustaining social programs.
On the basis of epidemiologic, clinical, micro-
biologic, and biochemical evidence, there is now
adequate evidence that 1) reproductive tract infec-
tion and subsequent inflammation cause significant
numbers of women to suffer preterm labor,
pPROM, and preterm birth; 2) these adverse ef-
fects are caused by infection and inflammation of
upper reproductive tract organs and tissues (i.e.,
placenta, decidua, amnionchorion); 3) the majority
of these infections arise from lower reproductive
tract sources including BV, cervicitis, or abnormal
colonization (enteropharyngeal pathogens, includ-
ing coliforms); and 4) many of these preterm births
are preventable with prompt diagnosis and sys-
temic (oral) antibiotic treatment during pregnancy.
Future studies will focus on more accurately defin-
ing women and babies at risk, elucidating patho-
genic interactions between microbes and both ma-
ternal and fetal hosts, and refining diagnostic and
treatment strategies so as to provide maximum
benefits while incurring minimal adverse effects
and costs.
Medical care providers now have new opportu-
nities and obligations to prevent as many infection-
mediated births as possible by identifying and
treating prevalent reproductive tract infections in
their patients. We wager that optimal approaches
will be shown to include identification and treat-
ment of susceptible women prior to pregnancy, as
part of preconceptual counseling and care.
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